Latest Insider Transactions at Esperion Therapeutics, Inc. (ESPR)
This section provides a real-time view of insider transactions for Esperion Therapeutics, Inc. (ESPR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Esperion Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Esperion Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 29
2021
|
Joanne M. Foody Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,450
+20.9%
|
-
|
|
Oct 29
2021
|
Richard Bartram Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,700
+29.9%
|
-
|
|
Oct 29
2021
|
Sheldon L. Koenig President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
26,700
+25.82%
|
-
|
|
Jun 28
2021
|
Joanne M. Foody Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
62,528
+50.0%
|
-
|
|
May 27
2021
|
Tracy M Woody Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,376
+30.34%
|
-
|
|
May 27
2021
|
Daniel Janney Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,376
+34.55%
|
-
|
|
May 27
2021
|
Nicole Vitullo Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,376
+28.04%
|
-
|
|
May 27
2021
|
Antonio M Jr Md D Phil Gotto Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,376
+34.55%
|
-
|
|
May 27
2021
|
Jay Shepard Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,376
+34.55%
|
-
|
|
May 27
2021
|
Mark E Mcgovern Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,376
+30.31%
|
-
|
|
May 27
2021
|
Alan Fuhrman Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,376
+32.89%
|
-
|
|
May 27
2021
|
Jeffrey Berkowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,376
+34.55%
|
-
|
|
May 24
2021
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
100,000
+2.18%
|
$2,000,000
$20.22 P/Share
|
|
May 19
2021
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
200,000
+4.37%
|
$4,000,000
$20.37 P/Share
|
|
May 17
2021
|
Sheldon L. Koenig President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+28.57%
|
-
|
|
May 06
2021
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
80,000
+1.88%
|
$1,600,000
$20.57 P/Share
|
|
May 05
2021
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
150,000
+3.53%
|
$3,000,000
$20.02 P/Share
|
|
Jan 28
2021
|
Sheldon L. Koenig President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
Jan 28
2021
|
Ashley Hall Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,000
+23.73%
|
-
|
|
Jan 28
2021
|
Richard Bartram Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+17.47%
|
-
|
|
Dec 30
2020
|
Timothy M Mayleben President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,700
+8.02%
|
$21,400
$2.1 P/Share
|
|
Nov 03
2020
|
Target N V Biotech > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
200,000
+4.82%
|
$5,000,000
$25.31 P/Share
|
|
Nov 05
2018
|
Boxer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
60,000
-0.88%
|
$3,420,000
$57.89 P/Share
|
|
Nov 02
2018
|
Boxer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
40,000
-1.67%
|
$2,160,000
$54.95 P/Share
|